Information Provided By:
Fly News Breaks for December 20, 2019
Dec 20, 2019 | 05:12 EDT
Piper Jaffray analyst Joseph Catanzaro raised his price target for Seattle Genetics to $130 from $120 after the FDA approved Padcev on an accelerated basis in post-platinum/checkpoint metastatic urothelial bladder cancer. The analyst says pricing for Padcev came in higher than his prior model assumption. He projects "strong initial uptake" in this setting based on "consistently positive" key opinion leader feedback and keeps an Overweight rating on Seattle Genetics.